Histopathological correlation of brain tumor recurrence vs. radiation effect post-radiosurgery as detected by MRI contrast clearance analysis: a validation study.
Brain tumors
Contrast clearance analysis
Histopathology
Radiation necrosis
Tumor progression
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
received:
02
04
2024
accepted:
23
04
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
15
5
2024
Statut:
aheadofprint
Résumé
The differentiation between adverse radiation effects (ARE) and tumor recurrence or progression (TRP) is a major decision-making point in the follow-up of patients with brain tumors. The advent of immunotherapy, targeted therapy and radiosurgery has made this distinction difficult to achieve in several clinical situations. Contrast clearance analysis (CCA) is a useful technique that can inform clinical decisions but has so far only been histologically validated in the context of high-grade gliomas. This is a series of 7 patients, treated between 2018 and 2023, for various brain pathologies including brain metastasis, atypical meningioma, and high-grade glioma. MRI with contrast clearance analysis was used to inform clinical decisions and patients underwent surgical resection as indicated. The histopathology findings were compared with the CCA findings in all cases. All seven patients had been treated with gamma knife radiosurgery and were followed up with periodic MR imaging. All patients underwent CCA when the necessity to distinguish tumor recurrence from radiation necrosis arose, and subsequently underwent surgery as indicated. Concordance of CCA findings with histological findings was found in all cases (100%). Based on prior studies on GBM and the surgical findings in our series, delayed contrast extravasation MRI findings correlate well with histopathology across a wide spectrum of brain tumor pathologies. CCA can provide a quick diagnosis and have a direct impact on patients' treatment and outcomes.
Identifiants
pubmed: 38748050
doi: 10.1007/s11060-024-04697-0
pii: 10.1007/s11060-024-04697-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Langer CJ, Mehta MP (2005) Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23:6207–6219. https://doi.org/10.1200/JCO.2005.03.145
doi: 10.1200/JCO.2005.03.145
pubmed: 16135488
Yu Y, Chen H, Tian Z, Zhang Q, Shui Y, Shen L, Hu Q, Huang Z, Zhu S, Jiang H, Wei Q (2023) Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases. J Neurooncol 165:127–137. https://doi.org/10.1007/s11060-023-04459-4
doi: 10.1007/s11060-023-04459-4
pubmed: 37848757
pmcid: 10638122
Zach L, Guez D, Last D, Daniels D, Grober Y, Nissim O, Hoffmann C, Nass D, Talianski A, Spiegelmann R, Tsarfaty G, Salomon S, Hadani M, Kanner A, Blumenthal DT, Bukstein F, Yalon M, Zauberman J, Roth J, Shoshan Y, Fridman E, Wygoda M, Limon D, Tzuk T, Cohen ZR, Mardor Y (2015) Delayed contrast extravasation MRI: a new paradigm in neuro-oncology. Neuro Oncol 17:457–465. https://doi.org/10.1093/neuonc/nou230
doi: 10.1093/neuonc/nou230
pubmed: 25452395
Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ (2017) Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with Glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 134:495–504. https://doi.org/10.1007/s11060-017-2375-2
doi: 10.1007/s11060-017-2375-2
pubmed: 28382534
pmcid: 7893814
Manning P, Daghighi S, Rajaratnam MK, Parthiban S, Bahrami N, Dale AM, Bolar D, Piccioni DE, McDonald CR, Farid N (2020) Differentiation of progressive disease from pseudoprogression using 3D PCASL and DSC perfusion MRI in patients with glioblastoma. J Neurooncol 147:681–690. https://doi.org/10.1007/s11060-020-03475-y
doi: 10.1007/s11060-020-03475-y
pubmed: 32239431
Thomas AA, Arevalo-Perez J, Kaley T, Lyo J, Peck KK, Shi W, Zhang Z, Young RJ (2015) Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. J Neurooncol 125:183–190. https://doi.org/10.1007/s11060-015-1893-z
doi: 10.1007/s11060-015-1893-z
pubmed: 26275367
pmcid: 4726629
Umemura Y, Wang D, Peck KK, Flynn J, Zhang Z, Fatovic R, Anderson ES, Beal K, Shoushtari AN, Kaley T, Young RJ (2020) DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. J Neurooncol 146:339–346. https://doi.org/10.1007/s11060-019-03379-6
doi: 10.1007/s11060-019-03379-6
pubmed: 31873875
Bodensohn R, Forbrig R, Quach S, Reis J, Boulesteix AL, Mansmann U, Hadi I, Fleischmann DF, Mucke J, Holzgreve A, Albert NL, Ruf V, Dorostkar M, Corradini S, Herms J, Belka C, Thon N, Niyazi M (2022) MRI-based contrast clearance analysis shows high differentiation accuracy between radiation-induced reactions and progressive disease after cranial radiotherapy. ESMO Open 7:100424. https://doi.org/10.1016/j.esmoop.2022.100424
doi: 10.1016/j.esmoop.2022.100424
pubmed: 35248822
pmcid: 9058918
Lim DH, Kim SY, Na YC, Cho JM (2023) Navigation guided Biopsy is as effective as Frame-based stereotactic biopsy. J Pers Med 13. https://doi.org/10.3390/jpm13050708
Mohamedkhan S, Hindocha S, de Boisanger J, Millard T, Welsh L, Rich P, MacKinnon AD, Williams N, Sharma B, Rosenfelder N, Minchom A (2024) Contrast Clearance Analysis (CCA) to assess viable Tumour following stereotactic radiosurgery (SRS) to Brain Metastasis in Non-small Cell Lung Cancer (NSCLC). Cancers (Basel) 16. https://doi.org/10.3390/cancers16061218
Zach L, Guez D, Last D, Daniels D, Grober Y, Nissim O, Hoffmann C, Nass D, Talianski A, Spiegelmann R, Cohen ZR, Mardor Y (2012) Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors. PLoS ONE 7:e52008. https://doi.org/10.1371/journal.pone.0052008
doi: 10.1371/journal.pone.0052008
pubmed: 23251672
pmcid: 3522646
Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Poschl J, Schuller U, Schichor C, Thon N, Tonn JC (2015) Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med 56:347–353. https://doi.org/10.2967/jnumed.114.149120
doi: 10.2967/jnumed.114.149120
pubmed: 25635133
Chen WC, Perlow HK, Choudhury A, Nguyen MP, Mirchia K, Youngblood MW, Lucas CG, Palmer JD, Magill ST, Raleigh DR (2022) Radiotherapy for meningiomas. J Neurooncol 160:505–515. https://doi.org/10.1007/s11060-022-04171-9
doi: 10.1007/s11060-022-04171-9
pubmed: 36315366
pmcid: 9722800